Pseudophakic reliability for you and your patients

The innovative XL optic of the ASPIRA-aXA combines the advantages of a 7.0 mm optic with the stability of the innovative cut-out haptic design, conveniently provided in the preloaded SAFELOADER^® implantation system.

• XL optic (Ø 7.0 mm) – For an extended view of the fundus 

       Reliable peripheral fundus view, ideal for patients at increased risk of retinal diseases

• XL optic (Ø 7.0 mm) – For large pupils

       Avoidance of interfering optical phenomena, especially in patients with large pupils

• Cut-out haptics – For more stability 

       Added stabilization for reliable refractive results

• Preloaded SAFELOADER^® – For more convenience 

       Convenient, astigmatism-neutral implantation through small incisions. Intuitive. Simple. Fast.

Monofocal 1P

ASPIRA-aXA

ASPIRA-aXA – versatile in application

ASPIRA-aXA provides a tailor-made solution for a diverse range of needs. Possible applications range from standard cataract and refractive surgeries to combined retinal surgery interventions.

XL SECURITY

    7.0MM OPTIC

XL STABILITY

    CUT-OUT HAPTIC

XL COMFORT

    PRELOADED SAFELOADER

Extended fundus view

• Due to its XL 7.0 mm optic, this posterior chamber lens supplies the best conditions for long-term pseudophakic reliability for the patient. The extended fundus view, which is enabled by the possibility of a rhexis diameter of up to 6.5 mm, represents an enormous contribution to preventive patient management and early detection of ocular diseases.

• Risk factors such as diabetes or hypertension are continuously increasing in our population.

• Especially for this group within the cataract patients, the ASPIRA-aXA lays the foundations for long-term pseudophakic reliability.

• From a vitreoretinal point of view, both the surgeon and the postoperative doctor benefit from the extended fundus view. The assessment of the posterior segment of the eye and the implementation of therapeutic measures for peripheral retinal diseases can occur more conveniently.

• ASPIRA-aXA offers patients with an increased risk of ocular diseases an advantage for long-term, successful pseudophakic treatment.

SAFELOADER^®

The ASPIRA-aXA is provided precisely and reliably by the unique autoloading SAFELOADER^® system:

• Easy to use – for more convenience 

  Intuitive, easy handling replaces manual catridge loading

• Separate components – for maximum safety 

  With its separate components, the preloaded implantation system offers the highest level of safety: both the IOL and the injector undergo separate sterilization processes

• Contactless one-way system 

  The separate storage of the IOL ensures that it only comes into contact with the coating additives of the cartridge immediately prior to the surgery

Premium IOL ASPIRA-aXA

The advantages of the premium IOL platform

• The high-precision manufacturing technology (Sub-nano resolution technology) enables the exact manufacturing of optic surfaces with an accuracy in the nanometer range. An additional production step – the polishing – which is often necessary with conventional IOLs and reduces the optical quality, can be omitted here. The result of this cutting-edge technology is an optic surface of premium HD quality for brilliant, clear, and sharp images.

• The aspherical optic design is aberration neutral, so no additional aberration is brought into the eye. It is suitable for all patients, regardless of the aberration of the cornea. Compared with spherical or aberration-correcting IOLs, patients benefit from increased contrast sensitivity or depth of field.

• 360° lens epithelial cell barrier and sharp optical edges offer effective prevention of postoperative posterior capsular opacification.

• Comfortable, astigmatism-neutral implantation with the preloaded SAFELOADER^® meets the highest demands and maximum safety in the OR.

• The IOL material is modeled on the natural lens. The hydrophilic acrylate is completely glistening-free and shows excellent uveal biocompatibility.

• Our premium IOLs are developed and produced exclusively in Germany according to the strictest quality specifications and stand for the highest quality with maximum product safety.

• Customer service and the experts from the application department are at your disposal for further information and your individual IOL calculation.

Clinical performance

What do the experts say?

Prof. G. Duncker, Halle

“The new ASPIRA-aXA combines an excellent, stable optic with easy in-the-bag implantation through a 2.0 mm incision. The patient response has been overwhelmingly positive.”

Personal Statement, 2018

Prof. W. Sekundo, Marburg

“The large ASPIRA-aXA optic has proven itself in phaco-vitrectomies because it allows an edge-free view into the outer retinal periphery.”

Personal Statement, 2018

Dr. Becker/Piskula, Oranienburg

“The ASPIRA-aXA with its enlarged XL optic represents a promising approach to minimize dysphotopsia.”

Piskula, M. Becker, E. (2018). Reduzierte pseudophake Dysphotopsien durch vergrößerte IOL-Optik. Presentation DGII 2018.

Takamura, MD, PhD

“The creation of a larger capsulorhexis with implantation of a 7.0 mm optic IOL contributed to a larger anterior capsule opening after cataract surgery in patients with DM [diabetes mellitus].”

Takamura, Y., et al. Large capsulorhexis with implantation of a 7,0 mm optic lens during cataract surgery in patients with diabetes mellitus. J Catract Refract Surg 2014; 40(11):1850-1856.